Test ID CRDPS Creatine Disorders Panel, Serum
Ordering Guidance
For diagnosis of creatine transporter deficiency, order CRDPU / Creatine Disorders Panel, Random, Urine.
Additional Testing Requirements
To diagnose all creatine deficiency syndromes, order CRDPU / Creatine Disorders Panel, Random, Urine in addition to this test.
Necessary Information
Patient's age and sex are required.
Specimen Required
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial. Send serum frozen.
Secondary ID
606131Useful For
Evaluating patients with a clinical suspicion of arginine:glycine amidinotransferase deficiency and guanidinoacetate methyltransferase deficiency using serum specimens
This test is not useful for the diagnosis of creatine transporter deficiency.
Testing Algorithm
For more information see:
-Newborn Screen Follow-up for Guanidinoacetate Methyltransferase Deficiency (GAMT)
-Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm
Special Instructions
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Creatine Disorders Panel, SSpecimen Type
SerumSpecimen Minimum Volume
0.1 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum | Frozen (preferred) | 14 days |
Refrigerated | 7 days | |
Ambient | 72 hours |
Clinical Information
Disorders of creatine synthesis (guanidinoacetate methyltransferase [GAMT], L-arginine:glycine amidinotransferases [AGAT], and creatine transporter deficiency [CTD]) are collectively described as creatine deficiency syndromes (CDS). GAMT and AGAT deficiencies are inherited in an autosomal recessive manner, while CTD is X-linked. All 3 disorders result in a depletion of cerebral creatine and typically present with global developmental delays, intellectual disability, and severe speech delay. Affected patients may have abnormal magnetic resonance imaging findings and exhibit cerebral creatine deficiency in brain magnetic resonance spectroscopy. Patients with GAMT and male patients with CTD develop seizures, behavioral problems, and autistic features and may have abnormal movements. Female carriers for CTD can be asymptomatic or exhibit features similar to affected male patients, such as intellectual disability, behavioral problems, and seizures.
Diagnosis of creatine synthesis disorders relies on measurement of guanidinoacetate (GAA), creatine (Cr), and creatinine (Crn) in serum and urine. The profiles are specific for each clinical entity. In serum, patients with GAMT deficiency typically exhibit very elevated GAA, low Cr, and normal to low Crn. Patients with AGAT deficiency typically exhibit low to normal GAA, low Cr, and normal to low Crn. In comparison, patients with CTD typically have normal serum levels of GAA, Cr and Crn, and measurement of these analytes in urine is required for diagnosis in male patients (characteristic findings are elevated Cr, normal to low Crn, and an elevated Cr:Crn ratio in urine). The only reliable method for diagnosis of CTD in female patients is molecular analysis of the SLC6A8 gene. The diagnosis of GAMT and AGAT can be confirmed by molecular analysis of GAMT and GATM.
Treatment with oral supplementation of creatine monohydrate is available and effective for the AGAT and GAMT deficiencies. Patients with GAMT deficiency may also be treated with supplemental ornithine and dietary arginine restriction.
Early treatment has been reported to prevent disease manifestations in affected but presymptomatic newborn siblings of individuals with GAMT or AGAT deficiencies.
Reference Values
Creatine Disorders Panel Reference Values |
||||||
|
≤11 Months |
12-23 Months |
24-35 Months |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
38.6-96.8 |
39.0-97.0 |
38.2-96.5 |
38.6-96.5 |
37.7-96.0 |
38.2-96.0 |
Creatinine |
27.6-35.9 |
27.6-35.2 |
27.6-36.5 |
27.6-35.5 |
27.6-37.1 |
27.6-36.0 |
Guanidinoacetate |
0.7-2.0 |
0.7-2.1 |
0.7-2.0 |
0.7-2.1 |
0.7-2.0 |
0.7-2.1 |
Creatine/ |
≤3.07 |
≤3.60 |
≤3.02 |
≤3.54 |
≤2.96 |
≤3.48 |
Guanidinoacetate/ |
≤0.040 |
≤0.040 |
≤0.042 |
≤0.040 |
≤0.043 |
≤0.042 |
Guanidinoacetate/ |
≤0.051 |
≤0.081 |
≤0.051 |
≤0.080 |
≤0.051 |
≤0.079 |
|
3 Years |
4 Years |
5 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
37.1-95.5 |
37.7-95.3 |
36.0-94.4 |
36.8-94.1 |
34.6-93.2 |
35.6-92.7 |
Creatinine |
27.6-37.9 |
27.7-36.9 |
27.6-39.3 |
27.7-38.2 |
27.6-40.9 |
27.8-39.9 |
Guanidinoacetate |
0.7-2.1 |
0.7-2.2 |
0.7-2.1 |
0.7-2.2 |
0.7-2.1 |
0.7-2.2 |
Creatine/ |
≤2.89 |
≤3.40 |
≤2.77 |
≤3.26 |
≤2.64 |
≤3.09 |
Guanidinoacetate/ |
≤0.045 |
≤0.043 |
≤0.049 |
≤0.045 |
≤0.053 |
≤0.049 |
Guanidinoacetate/ |
≤0.050 |
≤0.077 |
≤0.050 |
≤0.075 |
≤0.049 |
≤0.072 |
|
6 Years |
7 Years |
8 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
33.0-91.7 |
34.3-91.0 |
31.2-90.0 |
32.7-89.2 |
29.2-88.1 |
31.0-87.3 |
Creatinine |
27.6-42.8 |
28.0-41.9 |
27.7-44.9 |
28.3-44.3 |
27.8-47.0 |
28.8-47.1 |
Guanidinoacetate |
0.7-2.1 |
0.7-2.3 |
0.7-2.1 |
0.8-2.3 |
0.8-2.1 |
0.8-2.4 |
Creatine/ |
≤2.49 |
≤2.91 |
≤2.33 |
≤2.70 |
≤2.17 |
≤2.49 |
Guanidinoacetate/ |
≤0.058 |
≤0.053 |
≤0.063 |
≤0.058 |
≤0.069 |
≤0.064 |
Guanidinoacetate/ |
≤0.049 |
≤0.069 |
≤0.048 |
≤0.066 |
≤0.047 |
≤0.063 |
|
9 Years |
10 Years |
11 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
27.2-85.9 |
29.3-85.2 |
25.2-83.7 |
27.4-83.1 |
23.4-81.3 |
25.7-80.9 |
Creatinine |
28.0-49.3 |
29.5-50.1 |
28.2-51.5 |
30.6-53.6 |
28.4-53.6 |
32.0-57.2 |
Guanidinoacetate |
0.8-2.2 |
0.8-2.5 |
0.9-2.2 |
0.9-2.6 |
0.9-2.2 |
1.0-2.6 |
Creatine/ |
≤2.02 |
≤2.28 |
≤1.86 |
≤2.07 |
≤1.72 |
≤1.87 |
Guanidinoacetate/ |
≤0.075 |
≤0.070 |
≤0.081 |
≤0.078 |
≤0.087 |
≤0.085 |
Guanidinoacetate/ |
≤0.047 |
≤0.060 |
≤0.046 |
≤0.057 |
≤0.045 |
≤0.055 |
|
12 Years |
13 Years |
14 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
21.7-78.7 |
23.9-78.6 |
20.3-76.2 |
22.3-76.2 |
19.0-73.6 |
20.8-73.8 |
Creatinine |
28.7-55.7 |
33.8-61.0 |
29.1-57.7 |
35.9-64.8 |
29.5-59.5 |
38.1-68.5 |
Guanidinoacetate |
0.9-2.2 |
1.0-2.7 |
1.0-2.3 |
1.1-2.8 |
1.0-2.3 |
1.1-2.9 |
Creatine/ |
≤1.58 |
≤1.68 |
≤1.45 |
≤1.50 |
≤1.33 |
≤1.34 |
Guanidinoacetate/ |
≤0.092 |
≤0.093 |
≤0.097 |
≤0.101 |
≤0.101 |
≤0.109 |
Guanidinoacetate/ |
≤0.044 |
≤0.053 |
≤0.043 |
≤0.051 |
≤0.042 |
≤0.050 |
|
15 Years |
16 Years |
17 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
18.1-71.1 |
19.5-71.2 |
17.4-68.7 |
18.4-68.6 |
16.9-66.5 |
17.4-65.9 |
Creatinine |
29.9-61.3 |
40.4-71.9 |
30.4-62.9 |
42.4-75.0 |
30.9-64.4 |
44.2-77.6 |
Guanidinoacetate |
1.0-2.3 |
1.2-2.9 |
1.1-2.3 |
1.3-3.0 |
1.1-2.3 |
1.3-3.1 |
Creatine/ |
≤1.22 |
≤1.20 |
≤1.12 |
≤1.07 |
≤1.04 |
≤0.97 |
Guanidinoacetate/ |
≤0.104 |
≤0.117 |
≤0.107 |
≤0.125 |
≤0.109 |
≤0.132 |
Guanidinoacetate/ |
≤0.041 |
≤0.049 |
≤0.040 |
≤0.048 |
≤0.040 |
≤0.048 |
|
18 Years |
19 Years |
20 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
16.7-64.4 |
16.6-63.3 |
16.6-62.7 |
15.8-60.7 |
16.5-61.1 |
15.2-58.3 |
Creatinine |
31.3-65.8 |
45.6-80.0 |
31.8-67.0 |
46.7-82.0 |
32.2-68.2 |
47.4-83.9 |
Guanidinoacetate |
1.1-2.4 |
1.4-3.1 |
1.1-2.4 |
1.4-3.2 |
1.1-2.4 |
1.5-3.2 |
Creatine/ |
≤0.98 |
≤0.87 |
≤0.93 |
≤0.80 |
≤0.89 |
≤0.73 |
Guanidinoacetate/ |
≤0.111 |
≤0.139 |
≤0.112 |
≤0.145 |
≤0.113 |
≤0.150 |
Guanidinoacetate/ |
≤0.039 |
≤0.047 |
≤0.038 |
≤0.047 |
≤0.038 |
≤0.046 |
|
21 Years |
22 Years |
23 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
16.6-59.8 |
14.7-56.0 |
16.6-58.8 |
14.2-54.0 |
16.7-57.9 |
13.7-52.2 |
Creatinine |
32.5-69.2 |
47.9-85.6 |
32.8-70.2 |
48.2-87.2 |
33.1-71.1 |
48.4-88.8 |
Guanidinoacetate |
1.1-2.4 |
1.5-3.2 |
1.1-2.5 |
1.5-3.3 |
1.1-2.5 |
1.6-3.3 |
Creatine/ |
≤0.87 |
≤0.68 |
≤0.85 |
≤0.64 |
≤0.84 |
≤0.61 |
Guanidinoacetate/ |
≤0.114 |
≤0.156 |
≤0.115 |
≤0.161 |
≤0.116 |
≤0.165 |
Guanidinoacetate/ |
≤0.037 |
≤0.045 |
≤0.037 |
≤0.045 |
≤0.037 |
≤0.044 |
|
24 Years |
25 Years |
26 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
16.7-57.2 |
13.3-50.6 |
16.7-56.5 |
12.9-49.3 |
16.7-56.0 |
12.5-48.1 |
Creatinine |
33.3-71.9 |
48.6-90.2 |
33.6-72.8 |
48.7-91.5 |
33.7-73.6 |
48.9-92.7 |
Guanidinoacetate |
1.1-2.5 |
1.6-3.3 |
1.1-2.5 |
1.6-3.3 |
1.1-2.6 |
1.6-3.4 |
Creatine/ |
≤0.84 |
≤0.58 |
≤0.84 |
≤0.56 |
≤0.84 |
≤0.54 |
Guanidinoacetate/ |
≤0.116 |
≤0.170 |
≤0.117 |
≤0.174 |
≤0.118 |
≤0.179 |
Guanidinoacetate/ |
≤0.036 |
≤0.043 |
≤0.036 |
≤0.043 |
≤0.036 |
≤0.042 |
|
27 Years |
28 Years |
29 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
16.7-55.5 |
12.1-47.1 |
16.6-55.1 |
11.8-46.3 |
16.5-54.7 |
11.5-45.4 |
Creatinine |
33.9-74.4 |
49.0-93.7 |
34.1-75.2 |
49.1-94.5 |
34.2-76.0 |
49.2-95.3 |
Guanidinoacetate |
1.1-2.6 |
1.6-3.4 |
1.1-2.6 |
1.6-3.4 |
1.1-2.6 |
1.6-3.4 |
Creatine/ |
≤0.84 |
≤0.52 |
≤0.84 |
≤0.51 |
≤0.84 |
≤0.49 |
Guanidinoacetate/ |
≤0.118 |
≤0.182 |
≤0.119 |
≤0.186 |
≤0.119 |
≤0.188 |
Guanidinoacetate/ |
≤0.036 |
≤0.042 |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.041 |
|
30 Years |
31 Years |
32 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
16.4-54.2 |
11.3-44.7 |
16.4-53.8 |
11.1-43.9 |
16.3-53.4 |
11.0-43.2 |
Creatinine |
34.4-76.8 |
49.3-96.0 |
34.6-77.5 |
49.3-96.7 |
34.7-78.2 |
49.4-97.4 |
Guanidinoacetate |
1.2-2.7 |
1.6-3.5 |
1.2-2.7 |
1.6-3.5 |
1.2-2.7 |
1.6-3.5 |
Creatine/ |
≤0.84 |
≤0.48 |
≤0.83 |
≤0.47 |
≤0.83 |
≤0.46 |
Guanidinoacetate/ |
≤0.120 |
≤0.190 |
≤0.120 |
≤0.192 |
≤0.119 |
≤0.192 |
Guanidinoacetate/ |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.042 |
≤0.037 |
≤0.042 |
|
33 Years |
34 Years |
35 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
16.3-53.0 |
10.9-42.5 |
16.4-52.7 |
10.8-41.7 |
16.4-52.3 |
10.7-41.0 |
Creatinine |
34.9-78.8 |
49.4-98.0 |
35.1-79.4 |
49.5-98.6 |
35.3-79.9 |
49.5-99.2 |
Guanidinoacetate |
1.2-2.8 |
1.6-3.5 |
1.2-2.8 |
1.6-3.5 |
1.2-2.8 |
1.6-3.4 |
Creatine/ |
≤0.82 |
≤0.45 |
≤0.82 |
≤0.45 |
≤0.82 |
≤0.44 |
Guanidinoacetate/ |
≤0.119 |
≤0.192 |
≤0.118 |
≤0.191 |
≤0.118 |
≤0.189 |
Guanidinoacetate/ |
≤0.037 |
≤0.042 |
≤0.037 |
≤0.042 |
≤0.037 |
≤0.042 |
|
36 Years |
37 Years |
38 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
16.5-52.0 |
10.7-40.2 |
16.7-51.6 |
10.6-39.5 |
16.9-51.3 |
10.6-38.9 |
Creatinine |
35.4-80.3 |
49.5-99.8 |
35.6-80.7 |
49.5-100.3 |
35.8-81.0 |
49.6-100.8 |
Guanidinoacetate |
1.2-2.8 |
1.6-3.4 |
1.2-2.8 |
1.6-3.4 |
1.2-2.9 |
1.6-3.4 |
Creatine/ |
≤0.82 |
≤0.44 |
≤0.82 |
≤0.44 |
≤0.83 |
≤0.44 |
Guanidinoacetate/ |
≤0.117 |
≤0.187 |
≤0.115 |
≤0.184 |
≤0.114 |
≤0.182 |
Guanidinoacetate/ |
≤0.037 |
≤0.042 |
≤0.037 |
≤0.042 |
≤0.036 |
≤0.042 |
|
39 Years |
40 Years |
41 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
17.1-51.1 |
10.6-38.2 |
17.3-50.9 |
10.7-37.7 |
17.5-50.8 |
10.7-37.2 |
Creatinine |
35.9-81.4 |
49.6-101.3 |
36.0-81.6 |
49.6-101.7 |
36.1-81.9 |
49.7-102.1 |
Guanidinoacetate |
1.2-2.9 |
1.6-3.4 |
1.2-2.9 |
1.6-3.4 |
1.2-2.9 |
1.6-3.4 |
Creatine/ |
≤0.83 |
≤0.44 |
≤0.83 |
≤0.44 |
≤0.84 |
≤0.44 |
Guanidinoacetate/ |
≤0.113 |
≤0.179 |
≤0.111 |
≤0.176 |
≤0.110 |
≤0.174 |
Guanidinoacetate/ |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.040 |
|
42 Years |
43 Years |
44 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
17.7-50.8 |
10.8-36.7 |
17.8-50.8 |
10.9-36.3 |
17.8-50.9 |
11.0-36.0 |
Creatinine |
36.2-82.1 |
49.7-102.5 |
36.3-82.4 |
49.8-102.8 |
36.4-82.6 |
49.8-103.1 |
Guanidinoacetate |
1.2-3.0 |
1.6-3.3 |
1.2-3.0 |
1.6-3.3 |
1.2-3.0 |
1.6-3.3 |
Creatine/ |
≤0.84 |
≤0.44 |
≤0.84 |
≤0.43 |
≤0.84 |
≤0.43 |
Guanidinoacetate/ |
≤0.109 |
≤0.172 |
≤0.108 |
≤0.171 |
≤0.107 |
≤0.170 |
Guanidinoacetate/ |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.038 |
|
45 Years |
46 Years |
47 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
17.7-51.0 |
11.1-35.6 |
17.6-51.2 |
11.2-35.3 |
17.4-51.4 |
11.3-35.1 |
Creatinine |
36.4-82.8 |
49.9-103.4 |
36.5-83.0 |
49.9-103.6 |
36.5-83.2 |
49.9-103.9 |
Guanidinoacetate |
1.2-3.0 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
Creatine/ |
≤0.84 |
≤0.42 |
≤0.83 |
≤0.41 |
≤0.83 |
≤0.40 |
Guanidinoacetate/ |
≤0.106 |
≤0.169 |
≤0.106 |
≤0.168 |
≤0.106 |
≤0.167 |
Guanidinoacetate/ |
≤0.037 |
≤0.038 |
≤0.037 |
≤0.037 |
≤0.037 |
≤0.037 |
|
48 Years |
49 Years |
50 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
17.2-51.7 |
11.5-34.8 |
17.1-51.9 |
11.6-34.6 |
17.0-52.1 |
11.7-34.4 |
Creatinine |
36.6-83.4 |
49.9-104.1 |
36.6-83.5 |
49.9-104.2 |
36.7-83.7 |
49.9-104.4 |
Guanidinoacetate |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
Creatine/ |
≤0.82 |
≤0.39 |
≤0.82 |
≤0.38 |
≤0.82 |
≤0.38 |
Guanidinoacetate/ |
≤0.106 |
≤0.166 |
≤0.106 |
≤0.164 |
≤0.105 |
≤0.163 |
Guanidinoacetate/ |
≤0.038 |
≤0.036 |
≤0.038 |
≤0.036 |
≤0.039 |
≤0.036 |
|
51 Years |
52 Years |
53 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
17.0-52.2 |
11.9-34.3 |
17.1-52.3 |
12.0-34.3 |
17.3-52.4 |
12.2-34.3 |
Creatinine |
36.8-83.9 |
49.8-104.6 |
36.8-84.0 |
49.8-104.8 |
36.9-84.2 |
49.8-104.9 |
Guanidinoacetate |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.2 |
1.2-3.1 |
1.6-3.2 |
Creatine/ |
≤0.82 |
≤0.37 |
≤0.82 |
≤0.37 |
≤0.82 |
≤0.38 |
Guanidinoacetate/ |
≤0.105 |
≤0.161 |
≤0.104 |
≤0.159 |
≤0.103 |
≤0.157 |
Guanidinoacetate/ |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
|
54 Years |
55 Years |
56 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
17.6-52.5 |
12.4-34.3 |
18.1-52.6 |
12.5-34.4 |
18.6-52.7 |
12.6-34.4 |
Creatinine |
37.0-84.4 |
49.8-105.0 |
37.1-84.5 |
49.8-105.2 |
37.2-84.7 |
49.8-105.3 |
Guanidinoacetate |
1.2-3.1 |
1.6-3.2 |
1.2-3.1 |
1.6-3.2 |
1.2-3.1 |
1.6-3.2 |
Creatine/ |
≤0.82 |
≤0.38 |
≤0.83 |
≤0.39 |
≤0.84 |
≤0.40 |
Guanidinoacetate/ |
≤0.102 |
≤0.155 |
≤0.100 |
≤0.154 |
≤0.099 |
≤0.152 |
Guanidinoacetate/ |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
|
57 Years |
58 Years |
59 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
19.2-52.9 |
12.7-34.4 |
19.9-53.1 |
12.8-34.3 |
20.5-53.3 |
12.8-34.2 |
Creatinine |
37.3-84.9 |
49.8-105.4 |
37.4-85.1 |
49.8-105.5 |
37.6-85.2 |
49.8-105.6 |
Guanidinoacetate |
1.2-3.0 |
1.6-3.2 |
1.3-3.0 |
1.6-3.2 |
1.3-3.0 |
1.6-3.2 |
Creatine/ |
≤0.84 |
≤0.40 |
≤0.85 |
≤0.41 |
≤0.86 |
≤0.42 |
Guanidinoacetate/ |
≤0.098 |
≤0.151 |
≤0.096 |
≤0.151 |
≤0.095 |
≤0.150 |
Guanidinoacetate/ |
≤0.039 |
≤0.036 |
≤0.038 |
≤0.036 |
≤0.038 |
≤0.036 |
|
60 Years |
61 Years |
62 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
21.0-53.6 |
12.8-34.1 |
21.5-53.9 |
12.7-34.0 |
21.9-54.2 |
12.6-33.9 |
Creatinine |
37.8-85.4 |
49.9-105.7 |
38.0-85.5 |
49.9-105.9 |
38.3-85.7 |
49.9-106.0 |
Guanidinoacetate |
1.3-2.9 |
1.6-3.2 |
1.3-2.9 |
1.6-3.1 |
1.3-2.9 |
1.6-3.1 |
Creatine/ |
≤0.87 |
≤0.43 |
≤0.87 |
≤0.44 |
≤0.88 |
≤0.44 |
Guanidinoacetate/ |
≤0.094 |
≤0.150 |
≤0.093 |
≤0.150 |
≤0.093 |
≤0.150 |
Guanidinoacetate/ |
≤0.037 |
≤0.036 |
≤0.036 |
≤0.035 |
≤0.036 |
≤0.035 |
|
63 Years |
64 Years |
65 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
22.2-54.6 |
12.4-33.7 |
22.3-55.0 |
12.3-33.6 |
22.5-55.5 |
12.2-33.4 |
Creatinine |
38.7-85.8 |
50.0-106.1 |
39.1-85.9 |
50.0-106.3 |
39.6-86.1 |
50.1-106.4 |
Guanidinoacetate |
1.3-2.8 |
1.6-3.1 |
1.3-2.8 |
1.6-3.1 |
1.3-2.8 |
1.6-3.1 |
Creatine/ |
≤0.88 |
≤0.45 |
≤0.89 |
≤0.46 |
≤0.89 |
≤0.46 |
Guanidinoacetate/ |
≤0.092 |
≤0.150 |
≤0.092 |
≤0.149 |
≤0.091 |
≤0.149 |
Guanidinoacetate/ |
≤0.035 |
≤0.035 |
≤0.034 |
≤0.034 |
≤0.034 |
≤0.034 |
|
66 Years |
67 Years |
68 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
22.6-55.9 |
12.3-33.1 |
22.7-56.3 |
12.3-32.8 |
22.9-56.7 |
12.5-32.4 |
Creatinine |
40.2-86.2 |
50.2-106.6 |
40.7-86.3 |
50.3-106.7 |
41.3-86.5 |
50.4-106.9 |
Guanidinoacetate |
1.3-2.7 |
1.6-3.1 |
1.3-2.7 |
1.6-3.0 |
1.4-2.7 |
1.6-3.0 |
Creatine/ |
≤0.90 |
≤0.47 |
≤0.90 |
≤0.48 |
≤0.90 |
≤0.48 |
Guanidinoacetate/ |
≤0.091 |
≤0.149 |
≤0.090 |
≤0.148 |
≤0.090 |
≤0.148 |
Guanidinoacetate/ |
≤0.034 |
≤0.034 |
≤0.033 |
≤0.034 |
≤0.033 |
≤0.034 |
|
69 Years |
70 Years |
≥ 71 Years |
|||
Female |
Male |
Female |
Male |
Female |
Male |
|
Creatine |
23.2-57.0 |
12.8-32.0 |
23.6-57.2 |
13.1-31.4 |
24.1-57.3 |
13.6-30.8 |
Creatinine |
41.9-86.6 |
50.5-107.1 |
42.4-86.8 |
50.7-107.4 |
42.8-86.9 |
50.8-107.6 |
Guanidinoacetate |
1.4-2.6 |
1.6-3.0 |
1.4-2.6 |
1.6-3.0 |
1.4-2.5 |
1.5-3.0 |
Creatine/ |
≤0.90 |
≤0.48 |
≤0.90 |
≤0.48 |
≤0.90 |
≤0.48 |
Guanidinoacetate/ |
≤0.090 |
≤0.148 |
≤0.090 |
≤0.148 |
≤0.090 |
≤0.148 |
Guanidinoacetate/ |
≤0.033 |
≤0.034 |
≤0.033 |
≤0.034 |
≤0.033 |
≤0.034 |
Cautions
Creatine supplementation will cause falsely elevated creatine results and falsely decreased guanidinoacetate results.
Guanidinoacetate can be elevated in patients with urea cycle defects.
Day(s) Performed
Tuesday
Report Available
3 to 9 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82540
82565
82542